Figure 2.

Efficacy of OOS on SCLC models in vivo. (A) OOS interferes with tumor growth. Female CB17-SCID athymic mice were injected with 6×10⁶ GLC-8 cells. When tumors became palpable and maintained growth, they were randomized to different groups and were orally treated 5 days per week (Monday to Friday) with 100 μl OOS/animal or vehicle alone (water), and tumor volumes were measured twice a week. Data are represented as mean tumor volume ± SEM of the animals in each group. (B) Effect of OOS on animal weight. Statistical significant differences are shown (^*p<0.05). OOS, Ocoxin^® oral solution; SCLC, small cell lung cancer.